Down 13% from its year high at £116.50 now, AstraZeneca’s share price looks cheap to me anywhere under £219.81
AstraZeneca’s share price has dropped recently on concerns relating to its Chinese operation, but this may have left the ...
Hosted on MSN1h
UBS Upgrades AstraZeneca PLC - Depositary Receipt () (AZN)
Fintel reports that on February 13, 2025, UBS upgraded their outlook for AstraZeneca PLC - Depositary Receipt () ...
The AstraZeneca share price jumps 5% on today’s strong results – but is it too expensive?
Harvey Jones hails the brilliant long-term performance of the AstraZeneca share price, but wonders whether the FTSE 100's ...
Broker tips: AstraZeneca, Pan African Resources
UBS upgraded AstraZeneca from 'neutral' to 'buy' on Thursday, citing the pharmaceutical firm's "sector-leading" drug pipeline ...
Morgan Stanley sees huge upside at AstraZeneca
Morgan Stanley has initiated coverage of pharma giant AstraZeneca with an 'overweight' rating, recommending investors to ...
AstraZeneca initiated with an Overweight at Morgan Stanley
Morgan Stanley analyst Sarita Kapila initiated coverage of AstraZeneca (AZN) with an Overweight rating and 14,500 GBp price target The firm ...
London South East3d
Astrazeneca Share Chat (AZN)
The user of the website is referred to as "you" and "your". By posting on our share chat boards you are agreeing to the following: If you are going to post non-English, please also post an English ...
AstraZeneca Stock Rally Will be Tested by Answers on China Probe
A revival in AstraZeneca Plc shares faces a key test this week, with more likely to hinge on the drugmaker’s ability to ...
Business Weekly7d
AstraZeneca leads FTSE charge with shares surge and higher dividend
Growing at a rate of knots from the Cambridge Biomedical Campus, AstraZeneca hoisted its market cap to £183.58 billion and ...
AstraZeneca shares rise as China probe update reassures
AstraZeneca on Thursday said it could face a fine of up to $4.5 million in China over suspected unpaid import taxes, raising ...
The Motley Fool UK7d
The AstraZeneca share price jumps 5% on today’s strong results – but is it too expensive?
Harvey Jones hails the brilliant long-term performance of the AstraZeneca share price, but wonders whether the FTSE 100’s biggest company is just too pricey. When investing, your capital is at risk.